# US 2019/0390242 A1 · 3-alpha-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0390242 A1
- Document ID: US20190390242A1
- Status: Published application
- Kind: A1
- Application number: 16/561,643
- Filed: 2019-09-05
- Published: 2019-12-26
- Earliest claimed: 2014-08-12
- Assignees: PharmaZell GmbH
- Applicants: PharmaZell GmbH
- Inventors: Werner HUMMEL; Daniel BAKONYI
- Web page: https://patentgrep.com/patent/US20190390242A1

## CPC

- C12P 33/02: Dehydrogenating; Dehydroxylating
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12Y 101/0105: 3Alpha-hydroxysteroid 3-dehydrogenase (B-specific) (1.1.1.50)
- C12Y 101/01159: 7-Alpha-hydroxysteroid dehydrogenase (1.1.1.159)
- C12Y 101/01225: Chlordecone reductase (1.1.1.225)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention provides novel 3α-hydroxysteroid dehydrogenase mutants, sequences that code for these enzyme mutants, methods for producing the enzyme mutants, and o the use thereof in enzymatic reactions of cholic acid compounds, and in particular in the production of ursodeoxycholic acid (UDCA). The invention further provides processes for the synthesis of UDCA using the enzyme mutants and the production of UDCA using recombinant microorganisms that have been subjected to multiple modifications.

## Claims

### Claim 1

A 3α-hydroxysteroid dehydrogenase (3α-HSDH) that catalyzes at least the stereospecific enzymatic reduction of a 3-ketosteroid to the corresponding 3-hydroxysteroid, wherein the amino acid sequence of the 3α-HSDH has at least 80% sequence identity to SEQ ID NO:4 and has a mutation selected from the group consisting of:
a) dual mutation
R34X1/L68X2,
b) triple mutation P185X1/T188X3/L68X2,
wherein in said dual and triple mutations,
X1 represents A, T, S, G or V,
X2 represents A, G, C, K, S or V and
X3 represents A, G, W, S or V;
and c) mutations of a) or b), wherein the 3α-HSDH has a C-terminal extension of 1 to 10 histidine residues and/or an N-terminal extension of 1 to 10 histidine residues, wherein the amino acid numbering corresponds to the amino acid sequence of SEQ ID NO: 4.

### Claim 2 (depends on 1)

The 3α-hydroxysteroid dehydrogenase (3α-HSDH) of claim 1 that shows the following property profile in comparison with a 3α-HSDH consisting of the amino acid sequence of SEQ ID NO:4:
i) an increased specific activity (vmax [U/mg]) for dehydrocholic acid (DHCA) in the enzymatic reduction of DHCA with NADH as cofactor; or
ii) a reduced substrate inhibition by DHCA; or
iii) an increased specific activity (vmax [U/mg]) for NADH in the enzymatic reduction of DHCA with NADH as cofactor;
or iv) any combination of properties i), ii) and iii).

### Claim 3 (depends on 1, 2)

The 3α-hydroxysteroid dehydrogenase (3α-HSDH) of claim 1 or claim 2, wherein the amino acid sequence of the 3α-HSDH has at least 95% sequence identity to SEQ ID NO:4.

### Claim 4 (depends on 1, 2)

A nucleotide molecule comprising a nucleotide sequence that encodes the 3α-HSDH of claim 1 or claim 2.

### Claim 5 (depends on 1, 2)

An expression cassette comprising at least one nucleotide sequence encoding the 3α-HSDH of claim 1 or claim 2, wherein the expression of said nucleotide sequence is under the control of at least one regulatory sequence.

### Claim 6 (depends on 5)

An expression vector comprising at least one expression cassette of claim 5.

### Claim 7 (depends on 4)

A recombinant microorganism comprising at least one nucleic acid molecule of claim 4.

### Claim 8 (depends on 7)

The recombinant microorganism of claim 7 further comprising a nucleic acid molecule comprising a nucleotide sequence encoding an additional enzyme selected from the group consisting of hydroxysteroid dehydrogenases (HSDH) and cofactor regenerating dehydrogenases.

### Claim 9 (depends on 8)

The recombinant microorganism of claim 8, wherein the HSDH is selected from the group consisting of 7β-HSDHs that are NADPH- and/or NADH-dependent; and wherein the cofactor regenerating dehydrogenase is selected from the group consisting of NADPH-regenerating dehydrogenase enzymes and NADH-regenerating dehydrogenases enzymes.

### Claim 10 (depends on 9)

The recombinant microorganism of claim 9, wherein:
the NADPH-regenerating dehydrogenases are selected from the group consisting of NADPH dehydrogenases, NADPH-regenerating alcohol dehydrogenases (ADH), NADPH-regenerating formate dehydrogenases (FDH), NADPH-regenerating glucose dehydrogenase (GDH), NADPH-regenerating glucose-6-phosphate dehydrogenase (G-6-PDH) and NADPH-regenerating phosphite dehydrogenases (PtDH); and
the NADH-regenerating dehydrogenases are selected from the group consisting of NADH dehydrogenases, NADH-regenerating alcohol dehydrogenases (ADH), NADH-regenerating formate dehydrogenases (FDH), NADH-regenerating glucose dehydrogenases (GDH), NADH-regenerating glucose-6-phosphate dehydrogenases (G6PDH) and NADH-regenerating phosphite dehydrogenases (PtDH).

### Claim 11 (depends on 7)

The recombinant microorganism of claim 7 that is a 7α-HSDH knock-out strain.

### Claim 12 (depends on 1, 2, 7)

A process for the enzymatic or microbial synthesis of 3α-hydroxysteroids, comprising:
reducing a 3-ketosteroid in the presence of the 3α-HSDH of claim 1 or claim 2, or in the presence of the recombinant microorganism of claim 7 to the corresponding 3α-hydroxysteroid.

### Claim 13 (depends on 12)

The process of claim 12, wherein the 3-ketosteroid is selected from the group consisting of dehydrocholic acid (DHCA), a salt of DHCA, an amide of DHCA and an alkyl ester of DHCA.

### Claim 14 (depends on 12)

The process of claim 12 further comprising isolating the 3α-hydroxysteroid.

### Claim 15 (depends on 12)

The process of claim 12, wherein the 3-ketosteroid reduction takes place in the presence of NADPH and/or NADH.

### Claim 16 (depends on 15)

The process of claim 15, wherein the reaction takes place with the consumption of NADPH and/or NADH.

### Claim 17 (depends on 16)

The process of claim 16, wherein consumed NADPH is regenerated by coupling with an NADPH-regenerating enzyme, and/or wherein consumed NADH is regenerated by coupling with an NADH-regenerating enzyme.

### Claim 18 (depends on 17)

The process of claim 17, wherein:
the NADPH-regenerating enzyme is selected from the group consisting of NADPH dehydrogenases, NADPH-regenerating alcohol dehydrogenases (ADH), NADPH-regenerating formate dehydrogenases (FDH) and an NADPH-regenerating glucose dehydrogenase (GDH), and
the NADH-regenerating enzyme is selected from the group consisting of NADH-dehydrogenases, NADH-regenerating formate dehydrogenases (FDH), NADH-regenerating alcohol dehydrogenases (ADH), NADH-regenerating glucose-6-phosphate dehydrogenases (G6PDH), NADH-regenerating phosphite dehydrogenases (PtDH) and NADH-regenerating glucose dehydrogenases (GDH).

### Claim 19 (depends on 18)

The process of claim 18, wherein the NADPH-regenerating enzyme and/or the NADH-regenerating enzyme are expressed in a recombinant microorganism.

### Claim 20 (depends on 18)

The process of claim 18, wherein the NADPH-regenerating enzyme is selected from the group consisting of NADPH-regenerating formate dehydrogenases (FDH) and NADPH-regenerating glucose dehydrogenases (GDH).

### Claim 21 (depends on 1, 2)

A process for the preparation of ursodeoxycholic acid (UDCA) of formula (1)
in which
R represents alkyl, H, an alkali metal ion or N(R3)4+, wherein each R3 radical is identical or different and represents H or alkyl, or the group —CO2R is replaced by the acid amide group —CONR1R2, wherein R1 and R2 independently of one another represent an alkyl radical;
wherein the process comprises:
a) reducing dehyrocholic acid (DHCA) of formula (2)
in which R has the abovementioned meanings or the group —CO2R is replaced by the acid amide group —CONR1R2 as defined hereinabove;
in the presence of at least one 7β-HSDH and:
1) at least one 3α-HSDH of claim 1 or claim 2; and
2) at least one 3α-HSDH having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:4 and a mutation selected from the group consisting of:
a) single mutation P185X1 wherein X1 represents A, T, S, G or V,
b) single mutation T188X3 wherein X3 represents A, G, W, S or V, and
c) the mutation of a) or b), wherein the 3α-HSDH has a C-terminal extension of 1 to 10 histidine residues and/or an N-terminal extension of 1 to 10 histidine residues, wherein the amino acid numbering corresponds to the amino acid sequence of SEQ ID NO: 4;
to the corresponding 12-keto-ursodeoxycholic acid (12-keto UDCA) of formula (3)
in which R has the abovementioned meanings or the group —CO2R is replaced by the acid amide group —CONR1R2 as defined hereinabove; and
b) chemically reducing the 12-keto-UDCA of the formula (3) to the UDCA of formula (1).

### Claim 22 (depends on 21)

The process of claim 21, wherein the at least one 3α-HSDH has at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO:4.

### Claim 23 (depends on 1, 2, 21)

The process of claim 21, wherein at least step a) is carried out in the presence of the recombinant microorganism comprising at least one nucleic acid molecule that comprises a nucleotide sequence encoding:
1) the 3α-HSDH of claim 1 or claim 2, or
2) a 3α-HSDH having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO:4 and a mutation selected from the group consisting of:
a) single mutation P185X1 wherein X1 represents A, T, S, G or V,
b) single mutation T188X2 wherein X2 represents A, G, C, K, S or V, and
c) the mutation of a) or b), wherein the 3α-HSDH has a C-terminal extension of 1 to 10 histidine residues and/or an N-terminal extension of 1 to 10 histidine residues, wherein the amino acid numbering corresponds to the amino acid sequence of SEQ ID NO: 4.

### Claim 24 (depends on 23)

The process of claim 23, wherein the at least one 3α-HSDH has at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO:4.

### Claim 25 (depends on 21)

The process of claim 21, wherein step a) is coupled with identical or different cofactor regeneration systems.

### Claim 26 (depends on 21)

The process of claim 21, wherein step a) is carried out in the presence of and with the consumption of NADH and/or NADPH.

### Claim 27 (depends on 21)

The process of claim 21, further comprising purifying the ursodeoxycholic acid (UDCA) of formula (1).

### Claim 28 (depends on 21)

The process of claim 21 further comprising, prior to step a), chemically oxidizing a cholic acid (CA) of formula (2)
to a dehydrocholic acid (DHCA) of formula (4)
wherein in the compounds of formulas (2) and (4), R is as defined in claim 21, or the group
—CO2R is replaced by the acid amide group —CONR1R2 as defined in claim 21.
